Literature DB >> 19782789

Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial.

Allen E Atchley1, Dalane W Kitzman, David J Whellan, Ami E Iskandrian, Stephen J Ellis, Robert A Pagnanelli, Andrew Kao, Khaled Abdul-Nour, Christopher M O'Connor, Greg Ewald, William E Kraus, Salvador Borges-Neto.   

Abstract

BACKGROUND: There are currently limited data on the relationships between resting perfusion abnormalities, left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, and exercise capacity as defined by peak VO(2) and 6-minute walk test in patients with heart failure (HF) and reduced LVEF. Furthermore, the association between resting perfusion abnormalities and left ventricular dyssynchrony is currently unknown. This article addresses the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) gated SPECT imaging (gSPECT) substudy baseline results.
METHODS: HF-ACTION was a multicenter, randomized controlled trial of aerobic exercise training versus usual care in 2,331 stable patients with LVEF of < or = 35% and NYHA class II to IV HF symptoms treated with optimal medical therapy. Subjects enrolled in the HF-ACTION substudy underwent resting Tc-99m tetrofosmin gSPECT at baseline (n = 240). Images were evaluated for extent and severity of perfusion abnormalities using a 17-segment and a 5-degree gradation severity score (summed rest score [SRS]). Left ventricular function and dyssynchrony were assessed using validated available commercial software.
RESULTS: The average age of patients enrolled was 59, 69% were male, 63% were white, and 33% were African American. Of the 240 participants, 129 (54%) were ischemic and 111 (46%) were nonischemic in etiology. The median LVEF by gSPECT for the entire cohort was 26%. Among the nuclear variables, there was a modest correlation between LVEF and SRS (r = -0.31, P < .0001) and there were stronger correlations between phase SD and SRS (r = 0.66, P < .0001) as well as phase SD and LVEF (r = -0.50, P < .0001). Patients with NYHA class III symptoms had more severe and significant degrees of dyssynchrony (median phase SD 54 degrees ) than those with NYHA class II symptoms (median phase SD 39 degrees, P = .001). Patients with an ischemic etiology had a higher SRS (P < .0001) and significantly more dyssynchrony (P < .0001) than those who were nonischemic. However, there was no difference in LVEF or objective measures of exercise capacity between these groups. With respect to peak VO(2), there was a weak correlation with LVEF (r = 0.18, P = .006) and no correlation with SRS (r = -0.04, P = 0.59) or with dyssynchrony (r = -0.13, P = .09). A weak but statistically significant correlation between SRS and 6-minute walk was observed (r = -0.15, P = .047).
CONCLUSIONS: Gated SPECT imaging can provide important information in patients with HF due to severe LV dysfunction including quantitative measures of global systolic function, perfusion, and dyssynchrony. These measurements are modestly but significantly related to symptom severity and objective measures of exercise capacity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782789      PMCID: PMC2908486          DOI: 10.1016/j.ahj.2009.07.009

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  48 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

Authors:  James B Young; William T Abraham; Andrew L Smith; Angel R Leon; Randy Lieberman; Bruce Wilkoff; Robert C Canby; John S Schroeder; L Bing Liem; Shelley Hall; Kevin Wheelan
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

5.  Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.

Authors:  Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Robert Glazer; Nora Aknay; Allen Hester; Inder Anand; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

6.  Peak oxygen uptake better predicts outcome than submaximal respiratory data in heart transplant candidates.

Authors:  K Pardaens; J Van Cleemput; J Vanhaecke; R H Fagard
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

7.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

8.  Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy.

Authors:  Gabe B Bleeker; Theodorus A M Kaandorp; Hildo J Lamb; Eric Boersma; Paul Steendijk; Albert de Roos; Ernst E van der Wall; Martin J Schalij; Jeroen J Bax
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

9.  Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy.

Authors:  Peter G Danias; Georgios I Papaioannou; Alan W Ahlberg; David M O'Sullivan; April Mann; William E Boden; Gary V Heller
Journal:  Am J Cardiol       Date:  2004-07-01       Impact factor: 2.778

10.  Thallium 201 imaging and gated cardiac blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy. A clinical and pathologic study.

Authors:  B H Bulkley; G M Hutchins; I Bailey; H W Strauss; B Pitt
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

View more
  9 in total

1.  Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial.

Authors:  Allen E Atchley; Ami E Iskandrian; Dan Bensimhon; Stephen J Ellis; Dalane W Kitzman; Linda K Shaw; Robert A Pagnanelli; David J Whellan; Julius M Gardin; Andrew Kao; Khaled Abdul-Nour; Greg Ewald; Mary Norine Walsh; William E Kraus; Christopher M O'Connor; Salvador Borges-Neto
Journal:  Am Heart J       Date:  2011-04-06       Impact factor: 4.749

2.  Body mass index and rest myocardial perfusion defect predicts cardiac death in patients with chronic heart failure.

Authors:  Min Cai; Feng Wang; Jian Zhang; Zuo-Xiang He
Journal:  Int J Cardiovasc Imaging       Date:  2012-02-12       Impact factor: 2.357

3.  Benefits of cardiac rehabilitation in heart failure patients according to etiology: INCARD French study.

Authors:  François Koukoui; Franck Desmoulin; Gérard Lairy; Dominique Bleinc; Ludovic Boursiquot; Michel Galinier; Fatima Smih; Philippe Rouet
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

4.  Renal sympathetic denervation inhibits the development of left ventricular mechanical dyssynchrony during the progression of heart failure in dogs.

Authors:  Wei Hu; Qing-yan Zhao; Sheng-bo Yu; Bin Sun; Liao Chen; Sheng Cao; Rui-qiang Guo
Journal:  Cardiovasc Ultrasound       Date:  2014-11-22       Impact factor: 2.062

5.  Myocardial ischemia and previous infarction contribute to left ventricular dyssynchrony in patients with coronary artery disease.

Authors:  Hanna Hämäläinen; Alisa Corovai; Jussi Laitinen; Tiina M Laitinen; Marja Hedman; Antti Hedman; Antti Kivelä; Tomi P Laitinen
Journal:  J Nucl Cardiol       Date:  2020-08-31       Impact factor: 5.952

6.  New Trends in Quantitative Nuclear Cardiology Methods.

Authors:  Javier Gomez; Rami Doukky; Guido Germano; Piotr Slomka
Journal:  Curr Cardiovasc Imaging Rep       Date:  2018-01-19

7.  Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes.

Authors:  Francesco Di Pierro; Pietro Putignano; Nicola Villanova; Luca Montesi; Simona Moscatiello; Giulio Marchesini
Journal:  Clin Pharmacol       Date:  2013-11-19

8.  Role of Gated Myocardial Glucose Metabolic Imaging in Assessing Left Ventricular Systolic Dyssynchrony after Myocardial Infarction and the Influential Factors.

Authors:  Xiaoliang Shao; Jianfeng Wang; Yi Tian; Shengdeng Fan; Feifei Zhang; Wei Yang; Wenchong Xin; Yuetao Wang
Journal:  Sci Rep       Date:  2018-07-25       Impact factor: 4.379

9.  Synergistic prognostication of left ventricular hypertrophy and three-dimensional mechanical dyssynchrony in heart failure.

Authors:  Takahiro Doi; Tomoaki Nakata; Satoshi Yuda; Akiyoshi Hashimoto
Journal:  ESC Heart Fail       Date:  2020-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.